Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors

#937

Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.

Aim(s): To determine EVE tolerability and efficacy, in relationship with previous treatments, in a compassionate-use program.

Materials and methods: One-hundred and sixty-nine advanced progressive NETs treated with EVE evaluated: 85 pancreatic (pNETs), and 84 non-pancreatic (non-pNETs). Previous treatments were: somatostatin analogs 92.9%, PRRT 50.3%, chemotherapy 49.7%, PRRT and chemotherapy 22.8%.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Panzuto F, Rinzivillo M, Fazio N, De Braud F, Luppi G,

Keywords: Everolimus, compassionate use,